|
|
|
|
||
Absolut Silence....Sign OffWhat is or has happened to the FILM study? When or will the company announce the Q2 results as required by the SEC? Now that Aetna has approved the coverage of DermACELL, what has happened to the other two missing large insurance company coverage? The agreement with Stryker was to let them know daily the current results of the voting to approve the $11.75@ share buyout. I guess the shareholders will have to wait until it is over tomorrow whether to sell or hold until ....? My last thoughts: I think management could not breach the threshold of sales. Looking back we had indications galore. The addition of a metric of Revenue per sales person with a goal of $1.5-$2.0 million per rep...started at $0.4 increased to $0.8 then ...poof, we saw that metric dropped. Then the CEO mysteriously decided to leave. Then there was the change in emphasis from reaching Standard Of Care in Breast Reconstruction to...silence on the progress. Also there was the drop of mention of progress at the chronic wound care clinics (LUNA). Others too numerous to mention here, but the bottom line MANAGEMENT DID NOT HAVE THE HORSEPOWER TO CROSS THE FINISH LINE TO PROFITABILITY AND HOSPITAL PENETRATION. Hence they decided to sell to Stryker who will "Bolt" on this technology to their existing hospital sales network and using economies of Scope, increase the value beyond their marginal costs. If the technology revenue is really what NVDQ projected in the beginning, $2-$4 billion per year if one includes the world and not just the US, upper end. And the gross margins are ~65% to 75% and there marginal cost to sales, inventory, etc. are ~35% then in ~10 years the value added to Stryker should be ~$2*(1-.35-.35)= $600 to $1200 million in gross margins. If we take away 30%-35% for taxes the after tax benefit (stockholders) should be ~$400 to $800 million per year. With ~400 million shares that would be around $1 to $2 per share per year. With a current P/E of 32 and a cycle average of 16 that would mean the current SYK share price of $140 could add $16 to $64 (average $40) per share. Bottom line: This is all in todays dollars so that is a potential ~25% increase. But it needs to be shown credible and that would take years. Thanks to all that have contributed to this site on Novadaq. I had hoped for better. I'm sorry if anyone was hurt by my suggestions and analysis on this company. GSA |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
444 | Re: Absolut Silence....Sign Off | GlasgowGrip | 2 | 8/3/2017 5:45:41 PM |
446 | Re: Absolut Silence....Sign Off | buzzybob | 1 | 8/4/2017 3:53:42 PM |